168038-14-0

Basic information

• Product Name: (R)-2-Methyl-morpholine
• Synonyms: (R)-2-Methylmorpholine HCl;(R)-2-Methylmorpholine hydrochloride;(2R)-2-MethylMorpholine;Morpholine,2-Methyl-, hydrochloride (1:1), (2R)-;(R)-2-MethylMorpholine (N-Boc protected);(2R)-2-Methylmorpholine hydrochloride
• CAS NO: 168038-14-0
• Molecular Formula: C5H11NO
• Molecular Weight: 101.14694
• Mol File: 168038-14-0.mol

Chemical Properties

• Boiling Point: 137.1ºC at 760 mmHg
• Appearance: /
• Density: 0.891 g/cm3
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: (R)-2-Methyl-morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-Methyl-morpholine(168038-14-0)
• EPA Substance Registry System: (R)-2-Methyl-morpholine(168038-14-0)

Safety Data

• Hazardous Substances Data: 168038-14-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-Methyl-morpholine is used as a reactant in the preparation of naphthyridine as a hedgehog protein modulator. It plays a crucial role in the synthesis process, where it is derived from chloronicotinonitrile via aryl amination of naphthyridine halide. This application is significant in the development of drugs targeting the hedgehog signaling pathway, which is implicated in various diseases, including cancer and congenital disorders.
Additionally, due to its unique properties and reactivity, (R)-2-Methyl-morpholine can be employed as a building block or intermediate in the synthesis of other pharmaceuticals and organic compounds. Its chiral nature and ability to form stable complexes with various functional groups make it a versatile component in the design and development of new drugs and materials.

Upstream product

• 1004517-04-7 (R)-1-(benzyl(2-hydroxyethyl)amino)propan-2-ol 
• 845795-75-7 (R)-4-benzyl-2-methylmorpholine hydrochloride 
• 32730-38-4 4-benzyl-2-methyl-morpholine 

Downstream Products

• 1578244-99-1 N-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-8-(2-methylmorpholino)pyrido[3,4-d]pyrimidin-2-amine 

Relevant articles and documents

PYRAZOLO[3,4-D]PYRIMIDIN DERIVATIVE AND ITS USE FOR THE TREATMENT OF LEISHMANIASIS

The compound 3,3,3-trifluoro-N-((1,4-trans)-4-((3-((S)-2-methylmorpholino)-1H- pyrazolo[3,4-d]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sulfonamidehaving the Formula (I) or a salt thereof, its opposite enantiomer, compositions comprising the compound and its use in the treatment or prevention of leishmaniasis, particularly visceral leishmaniasis.

CHROMENONE COMPOUNDS AS PI 3 -KINASE INHIBITORS FOR THE TREATMENT OF CANCER

The invention concerns chromenone compounds of Formula I; or pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, n and R6 has any of the meanings defined hereinbe

CHROMENONE DERIVATIVES

The invention concerns chromenone compounds of Formula I; or pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, n and R6 has any of the meanings defined hereinbe

THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS

This invention relates to the use of thiazolopyrimidinone derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3' OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ

COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS

The invention provides a novel class of 2,7-naphthyridin derivatives; pharmaceutical compositions comprising such compounds and methods of using such compounds to treat o prevent diseases or disorders associated with abnormal or deregulated kinase activit

COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS

The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-fu

Compounds and compositions as inhibitors of receptor tyrosine kinase activity

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with cSRC, Lck, FGFR3, Flt3, TrkB, Bmx, and/or PFGFRα kinase

Quinolinecarboxylic acid derivatives, antibacterial agent containing the same

Novel quinolinecarboxylic acid derivatives of the formula: STR1 wherein Z is STR2 or STR3 in which R1 is hydrogen atom, a halogen atom, hydroxy or a lower alkyloxy; R2 is a halogen atom, hydroxy or a lower alkyloxy; R3 is a lower alkyl; and R4 is hydroxy or a di(lower alkyl)amino, and a pharmaceutically acceptable salt thereof, which have excellent antibacterial activities and are useful as an antibacterial agent, a pharmaceutical composition containing the same, and process for preparing the same.